Supermarket shelves are full of largely unregulated probiotics that aim to keep gut bacteria in balance. With its new drug Vowst, Seres has created something different: the first oral prescription treatment for the microbiome. Approved by the FDA in April, Vowst is a capsule full of carefully selected bacterial spores that together can suppress growth of C. difficile, which can cause life-threatening infections, and are a common complication in hospitals. In studies, Vowst was 88% effective in preventing repeat infections after two months. “This is a game changer for this patient population,” says Eric Shaff, president and CEO of Seres. It will be available starting in June.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
- Donald Trump Is TIME's 2024 Person of the Year
- Why We Chose Trump as Person of the Year
- Is Intermittent Fasting Good or Bad for You?
- The 100 Must-Read Books of 2024
- The 20 Best Christmas TV Episodes
- Column: If Optimism Feels Ridiculous Now, Try Hope
- The Future of Climate Action Is Trade Policy
- Merle Bombardieri Is Helping People Make the Baby Decision
